The association between comorbid autism spectrum disorders and antipsychotic treatment failure in early-onset psychosis: A historical cohort study using electronic health records

Journal of Clinical Psychiatry

Volumn 78, Issue 9, 2017, Pages e1233-e1241

  Downs, Johnny M ^a,b   Lechler, Suzannah ^a,b   Dean, Harry ^a,b   Sears, Nicola ^a,b   Patel, Rashmi ^a,b   Shetty, Hitesh ^b   Simonoff, Emily ^a,b   Hotopf, Matthew ^a,b   Ford, Tamsin J ^c   Diaz Caneja, Covadonga M ^d   Arango, Celso ^d   MacCabe, James H ^a,b   Hayes, Richard D ^a,b   Pina Camacho, Laura ^a,b,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ARTICLE; AUTISM; CHILD; COHORT ANALYSIS; COMORBIDITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HUMAN; HYPERKINESIA; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; COMPLICATION; ONSET AGE; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGY; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADOLESCENT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; AUTISM SPECTRUM DISORDER; CHILD; FEMALE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 85040082632     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.16m11422     Document Type: Article

References (52)

1. Schimmelmann BG, Conus P, Cotton S, et al. Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res. 2007;95(1–3):1–8.
2. Ballageer T, Malla A, Manchanda R, et al. Is adolescent-onset first-episode psychosis different from adult onset? JAmAcadChild AdolescPsychiatry. 2005;44(8):782–789.
3. Hui CL, Li AW, Leung CM, et al. Comparing illness presentation, treatment and functioning between patients with adolescent- and adult-onset psychosis. Psychiatry Res. 2014;220(3):797–802.
4. Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry. 2009;195(4):286–293.
5. Stentebjerg-Olesen M, Pagsberg AK, Fink-Jensen A, et al. Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review. JChild AdolescPsychopharmacol. 2016;26(5):410–427.
6. Díaz-Caneja CM, Pina-Camacho L, Rodríguez-Quiroga A, et al. Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophr. 2015;1:14005.
7. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8(3):470–484.
8. Del Rey-Mejías Á, Fraguas D, Díaz-Caneja CM, et al. Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis. EurChildAdolescPsychiatry. 2015;24(12):1447–1459.
9. Sporn AL, Addington AM, Gogtay N, et al. Pervasive developmental disorder and childhood-onset schizophrenia: comorbid disorder or a phenotypic variant of a very early onset illness? BiolPsychiatry. 2004;55(10):989–994.
10. Larson FV, Wagner AP, Jones PB, et al. Psychosis in autism: comparison of the features of both conditions in a dually affected cohort. Br J Psychiatry. 2017;210(4):269–275.
11. Khandaker GM, Stochl J, Zammit S, et al. A population-based longitudinal study of childhood neurodevelopmental disorders, IQ and subsequent risk of psychotic experiences in adolescence. PsycholMed. 2014;44(15):3229–3238.
12. Pina-Camacho L, Parellada M, Kyriakopoulos M. Autism spectrum disorder and schizophrenia: boundaries and uncertainties. BJPsychAdv. 2016;22(5):316–324.
13. Hassan GAM, Taha GRA. Long term functioning in early onset psychosis: two years prospective follow-up study. Behav Brain Funct. 2011;7:28.
14. Fleischhaker C, Schulz E, Tepper K, et al. Long-term course of adolescent schizophrenia. Schizophr Bull. 2005;31(3):769–780.
15. Starling J, Dossetor D. Pervasive developmental disorders and psychosis. Curr Psychiatry Rep. 2009;11(3):190–196.
16. Sheitman BB, Kraus JE, Bodfish JW, et al. Are the negative symptoms of schizophrenia consistent with an autistic spectrum illness? Schizophr Res. 2004;69(1):119–120.
17. Frank J, Lang M, Witt SH, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. MolPsychiatry. 2015;20(2):150–151.
18. Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in autism spectrum disorder. Harv Rev Psychiatry. 2014;22(2):76–92.
19. Rapoport J, Chavez A, Greenstein D, et al. Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. JAmAcad ChildAdolescPsychiatry. 2009;48(1):10–18.
20. Perera G, Broadbent M, Callard F, et al. Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an electronic mental health record-derived data resource. BMJOpen. 2016;6(3):e008721.
21. Cunningham H. GATE, a General Architecture for Text Engineering. ComputHum. 2002;36(2):223–254.
22. National Collaborating Centre for Mental Health (UK). Psychosis and Schizophrenia in Children and Young People: Recognition and Management. Leicester, UK: British Psychological Society; 2013.
23. Correll CU, Kishimoto T, Nielsen J, et al. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33(12):B16–B39.
24. Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012;197(1–2):1–6.
25. Schneider C, Papachristou E, Wimberley T, et al. Clozapine use in childhood and adolescent schizophrenia: a nationwide population-based study. Eur Neuropsychopharmacol. 2015;25(6):857–863.
26. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEnglJMed. 2005;353(12):1209–1223.
27. Patel R, Wilson R, Jackson R, et al. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJOpen. 2016;6(3):e009888.
28. Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097.
29. Downs J, Hotopf M, Ford T, et al. Clinical predictors of antipsychotic use in children and adolescents with autism spectrum disorders: a historical open cohort study using electronic health records. EurChildAdolescPsychiatry. 2016;25(6):649–658.
30. Hayes RD, Downs J, Chang C-K, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2015;41(3):644–655.
31. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007;68(suppl 1):12–19.
32. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet. 2006;368(9531):210–215.
33. Lord C, Rutter M, DiLavore P, et al. Autism Diagnostic Observation Schedule (ADOS). Los Angeles, CA: Western Psychological Services; 2000.
34. Volkmar F, Siegel M, Woodbury-Smith M, et al; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. JAmAcadChildAdolescPsychiatry. 2014;53(2):237–257.
35. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. JAutismDevDisord. 1994;24(5):659–685.
36. McLennan D, Barnes H, Noble M, et al. The English Indices of Deprivation 2010. London, UK: Department for Communities and Local Government; 2011.
37. Shaffer D, Gould MS, Brasic J, et al. A children’s global assessment scale (CGAS). ArchGen Psychiatry. 1983;40(11):1228–1231.
38. Rabinowitz J, Harvey PD, Eerdekens M, et al. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006;189:31–35.
39. Rabinowitz J, Napryeyenko O, Burba B, et al. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. JClinPsychopharmacol. 2011;31(1):75–81.
40. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. ArchGen Psychiatry. 2005;62(11):1266–1274.
41. Kästner A, Begemann M, Michel TM, et al. Autism beyond diagnostic categories: characterization of autistic phenotypes in schizophrenia. BMCPsychiatry. 2015;15:115.
42. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. BiolPsychiatry. 2014;75(5):e11–e13.
43. Lin K-M, Poland R. Ethnicity, culture, and psychopharmacology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The Fourth Generation of Progress. New York, NY: American College of Neuropsycopharmacology, Raven Press; 2000:1907–1917.
44. McCutcheon R, Beck K, Bloomfield MAP, et al. Treatment resistant or resistant to treatment? antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. JPsychopharmacol. 2015;29(8):892–897.
45. Meng H, Schimmelmann BG, Mohler B, et al. Pretreatment social functioning predicts 1-year outcome in early onset psychosis. Acta Psychiatr Scand. 2006;114(4):249–256.
46. Wimberley T, Støvring H, Sørensen HJ, et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. LancetPsychiatry. 2016;3(4):358–366.
47. Findling RL, Johnson JL, McClellan J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. JAmAcadChildAdolescPsychiatry. 2010;49(6):583–594, quiz 632.
48. Kumra S, Jacobsen LK, Lenane M, et al. “Multidimensionally impaired disorder”: is it a variant of very early-onset schizophrenia? JAm AcadChildAdolescPsychiatry. 1998;37(1):91–99.
49. Buitelaar JK, van der Gaag RJ. Diagnostic rules for children with PDD-NOS and multiple complex developmental disorder. JChild PsycholPsychiatry. 1998;39(6):911–919.
50. Kyriakopoulos M, Stringaris A, Manolesou S, et al. Determination of psychosis-related clinical profiles in children with autism spectrum disorders using latent class analysis. Eur Child Adolesc Psychiatry. 2015;24(3):301–307.
51. Remschmidt H, Theisen F. Early-onset schizophrenia. Neuropsychobiology. 2012;66(1):63–69.
52. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71(9):1115–1124.